Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005839 · ClinicalTrials.gov registry record · Phase 1
Oxaliplatin Plus Capecitabine in Treating Patients With Metastatic or Recurrent Solid Tumor
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00005839: Completed Phase 1 study, sponsored by City of Hope Medical Center.
NCT00005839 is a Phase 1 study that has completed, run by City of Hope Medical Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005839, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of oxaliplatin combined with capecitabine in treating patients who have metastatic or recurrent solid tumors.
Interventions
- DRUG oxaliplatin
- DRUG capecitabine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-08 |
| Est. Completion | 2004-06 |
| Phase | Phase 1 |
What the finished NCT00005839 record still lists
NCT00005839 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which oxaliplatin is the first listed.
NCT00005839 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005839 about?
NCT00005839 is a clinical study titled "Oxaliplatin Plus Capecitabine in Treating Patients With Metastatic or Recurrent Solid Tumor". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of oxaliplatin combined with capecitabine in treating patients who have m...
What is the current status of trial NCT00005839?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-08. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00005839?
The interventions under investigation include: oxaliplatin (DRUG), capecitabine (DRUG).
Who is sponsoring clinical trial NCT00005839?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia